Literature DB >> 11923333

Ribosomal DNA-directed PCR for identification of Achromobacter (Alcaligenes) xylosoxidans recovered from sputum samples from cystic fibrosis patients.

Lixia Liu1, Tom Coenye, Jane L Burns, Paul W Whitby, Terrence L Stull, John J LiPuma.   

Abstract

The opportunistic human pathogen Achromobacter (Alcaligenes) xylosoxidans has been recovered with increasing frequency from respiratory tract culture of persons with cystic fibrosis (CF). However, confusion of this species with other closely related respiratory pathogens has limited studies to better elucidate its epidemiology, natural history, and pathogenic role in CF. Misidentification of A. xylosoxidans as Burkholderia cepacia complex is especially problematic and presents a challenge to effective infection control in CF. To address the problem of accurate identification of A. xylosoxidans, we developed a PCR assay based on a 16S ribosomal DNA sequence. In an analysis of 149 isolates that included 47 A. xylosoxidans and several related glucose-nonfermenting species recovered from CF sputum, the sensitivity and specificity of this PCR assay were determined to be 100 and 97%, respectively. The availability of this assay will enhance identification of A. xylosoxidans, thereby facilitating study of the pathogenic role of this species and improving infection control efforts in CF.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11923333      PMCID: PMC140369          DOI: 10.1128/JCM.40.4.1210-1213.2002

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  30 in total

1.  Composition of soil microbial communities enriched on a mixture of aromatic hydrocarbons.

Authors:  E A Greene; J G Kay; K Jaber; L G Stehmeier; G Voordouw
Journal:  Appl Environ Microbiol       Date:  2000-12       Impact factor: 4.792

2.  A pseudoepidemic of Alcaligenes xylosoxidans attributable to contaminated saline.

Authors:  E V Granowitz; S L Keenholtz
Journal:  Am J Infect Control       Date:  1998-04       Impact factor: 2.918

3.  Recurrent Achromobacter piechaudii bacteremia in a patient with hematological malignancy.

Authors:  S E Kay; R A Clark; K L White; M M Peel
Journal:  J Clin Microbiol       Date:  2001-02       Impact factor: 5.948

4.  Identification and detection of Stenotrophomonas maltophilia by rRNA-directed PCR.

Authors:  P W Whitby; K B Carter; J L Burns; J A Royall; J J LiPuma; T L Stull
Journal:  J Clin Microbiol       Date:  2000-12       Impact factor: 5.948

5.  Species-specific PCR as a tool for the identification of Burkholderia gladioli.

Authors:  P W Whitby; L C Pope; K B Carter; J J LiPuma; T L Stull
Journal:  J Clin Microbiol       Date:  2000-01       Impact factor: 5.948

6.  DNA-Based diagnostic approaches for identification of Burkholderia cepacia complex, Burkholderia vietnamiensis, Burkholderia multivorans, Burkholderia stabilis, and Burkholderia cepacia genomovars I and III.

Authors:  E Mahenthiralingam; J Bischof; S K Byrne; C Radomski; J E Davies; Y Av-Gay; P Vandamme
Journal:  J Clin Microbiol       Date:  2000-09       Impact factor: 5.948

7.  Misidentification of Burkholderia cepacia in US cystic fibrosis treatment centers: an analysis of 1,051 recent sputum isolates.

Authors:  J D McMenamin; T M Zaccone; T Coenye; P Vandamme; J J LiPuma
Journal:  Chest       Date:  2000-06       Impact factor: 9.410

8.  Utility of commercial systems for identification of Burkholderia cepacia complex from cystic fibrosis sputum culture.

Authors:  D B Shelly; T Spilker; E J Gracely; T Coenye; P Vandamme; J J LiPuma
Journal:  J Clin Microbiol       Date:  2000-08       Impact factor: 5.948

9.  Recurrent Achromobacter xylosoxidans bacteremia associated with persistent lymph node infection in a patient with hyper-immunoglobulin M syndrome.

Authors:  J H Weitkamp; Y W Tang; D W Haas; N K Midha; J E Crowe
Journal:  Clin Infect Dis       Date:  2000-11-06       Impact factor: 9.079

10.  Isolation and characterization of an Achromobacter xylosoxidans strain B3 and other bacteria capable to degrade the synthetic chelating agent iminodisuccinate.

Authors:  F Reinecke; T Groth; K P Heise; W Joentgen; N Müller; A Steinbüchel
Journal:  FEMS Microbiol Lett       Date:  2000-07-01       Impact factor: 2.742

View more
  32 in total

1.  Surface analysis of nitrogen plasma-treated C60/PS nanocomposite films for antibacterial activity.

Authors:  Naglaa M El-Sayed; Fifi M Reda; Omar F Farag; Doaa A Nasrallah
Journal:  J Biol Phys       Date:  2017-05-04       Impact factor: 1.365

2.  Achromobacter xylosoxidans: characterization of strains in Brazilian cystic fibrosis patients.

Authors:  Rosana H V Pereira; Ana Paula Carvalho-Assef; Rodolpho M Albano; Tania W Folescu; Marcia C M F Jones; Robson S Leão; Elizabeth A Marques
Journal:  J Clin Microbiol       Date:  2011-08-17       Impact factor: 5.948

3.  Use of PCR analyses to define the distribution of Ralstonia species recovered from patients with cystic fibrosis.

Authors:  Tom Coenye; Theodore Spilker; Rebecca Reik; Peter Vandamme; John J Lipuma
Journal:  J Clin Microbiol       Date:  2005-07       Impact factor: 5.948

4.  Environmental Distribution and Drug Susceptibility of Achromobacter Xylosoxidans Isolated from Outdoor and Indoor Environments.

Authors:  Sachiko Nakamoto; Misaki Sakamoto; Kana Sugimura; Yuki Honmura; Yuki Yamamoto; Natsumi Goda; Hiroo Tamaki; Naoto Burioka
Journal:  Yonago Acta Med       Date:  2017-03-09       Impact factor: 1.641

Review 5.  The changing microbial epidemiology in cystic fibrosis.

Authors:  John J Lipuma
Journal:  Clin Microbiol Rev       Date:  2010-04       Impact factor: 26.132

6.  Energy-generating enzymes of Burkholderia cepacia and their interactions with macrophages.

Authors:  Vasu Punj; Rachna Sharma; Olga Zaborina; A M Chakrabarty
Journal:  J Bacteriol       Date:  2003-05       Impact factor: 3.490

7.  Airway infection with a novel Cupriavidus species in persons with cystic fibrosis.

Authors:  Wiltrud Maria Kalka-Moll; John J LiPuma; Frank J Accurso; Georg Plum; Silke van Koningsbruggen; Peter Vandamme
Journal:  J Clin Microbiol       Date:  2009-07-15       Impact factor: 5.948

8.  Infection by Ralstonia species in cystic fibrosis patients: identification of R. pickettii and R. mannitolilytica by polymerase chain reaction.

Authors:  Tom Coenye; Peter Vandamme; John J LiPuma
Journal:  Emerg Infect Dis       Date:  2002-07       Impact factor: 6.883

9.  PCR-based assay for differentiation of Pseudomonas aeruginosa from other Pseudomonas species recovered from cystic fibrosis patients.

Authors:  Theodore Spilker; Tom Coenye; Peter Vandamme; John J LiPuma
Journal:  J Clin Microbiol       Date:  2004-05       Impact factor: 5.948

10.  Recovery of Herbaspirillum species from persons with cystic fibrosis.

Authors:  Theodore Spilker; Ahmet Z Uluer; Francisco M Marty; Wendy W Yeh; Julie H Levison; Peter Vandamme; John J Lipuma
Journal:  J Clin Microbiol       Date:  2008-06-04       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.